Armodafinil
- PDF / 171,990 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 110 Downloads / 160 Views
1
S
Stevens-Johnson Syndrome: case report A 21-year-old woman developed Stevens-Johnson syndrome (SJS) during treatment with armodafinil for idiopathic hypersomnia. The woman had been receiving maintenance immunotherapy for unknown allergies. Her concomitant medications included colecalciferol [vitamin-D3], probiotics [Ultra Probiotic Complex], ethinylestradiol/norethisterone [Cyclafem], fexofenadine [Allegra], bismuth-salicylate [bismuth subsalicylat; Pepto-Bismol] and ibuprofen. She was diagnosed with idiopathic hypersomnia and started receiving oral armodafinil [Nuvigil] 150mg every morning. Approximately twelve days after the initiation of armodafinil, she developed mild fever and swelling of the neck consistent with cervical lymphadenopathy. The woman discontinued armodafinil. Within twelve hours of therapy discontinuation, she developed mucocutaneous ulcerations and irregular itchy macules on her face along with a generalised rash all over the body, which were suggestive of SJS. On the subsequent day, she was hospitalised and received supportive care. Her skin biopsy confirmed the diagnosis of SJS. Several weeks later, the symptoms had resolved. Three months later, only subtle discolouration of skin was seen over previously blistered areas. Author comment: "We present a case of a patient in whom [Stevens-Johnson Syndrome] developed less than 2 weeks after starting armodafinil." Holfinger S, et al. Stevens-Johnson Syndrome After Armodafinil Use. Journal of Clinical Sleep Medicine 14: 885-887, No. 5, 15 May 2018. Available from: URL: 803438907 http://doi.org/10.5664/jcsm.7132 - USA
»
Editorial comment: Details of this case report have previously been published [see Reactions 1656 p66; 803250375] [see Reactions 1705 p47; 803324339]
0114-9954/19/1783-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 14 Dec 2019 No. 1783
Data Loading...
